These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26598749)

  • 1. Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.
    Epstein AJ; Wong YN; Mitra N; Vachani A; Hin S; Yang L; Smith-McLallen A; Armstrong K; Groeneveld PW
    J Clin Oncol; 2015 Dec; 33(36):4259-67. PubMed ID: 26598749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.
    Dzimitrowicz H; Mougalian S; Storms S; Hurd S; Chagpar AB; Killelea BK; Horowitz NR; Lannin DR; Harigopal M; Hofstatter E; DiGiovanna MP; Adelson KB; Silber A; Abu-Khalaf M; Chung G; Zaheer W; Abdelghany O; Hatzis C; Pusztai L; Sanft TB
    J Oncol Pract; 2017 Dec; 13(12):e1012-e1020. PubMed ID: 29048991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer.
    Barlow WE; Taplin SH; Yoshida CK; Buist DS; Seger D; Brown M
    J Natl Cancer Inst; 2001 Mar; 93(6):447-55. PubMed ID: 11259470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
    Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
    JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
    Dinan MA; Wilson LE; Reed SD
    J Natl Compr Canc Netw; 2019 Mar; 17(3):245-254. PubMed ID: 30865923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
    Parsons BM; Landercasper J; Smith AL; Go RS; Borgert AJ; Dietrich LL
    Breast Cancer Res Treat; 2016 Sep; 159(2):315-26. PubMed ID: 27507245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
    Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
    Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
    Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
    JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
    Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.
    Henry NL; Braun TM; Ali HY; Munir K; Silver SM; Gorski DH; Breslin TM; Griggs JJ
    Cancer; 2017 May; 123(6):948-956. PubMed ID: 27787892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world economic value of a 21-gene assay in early-stage breast cancer.
    Waintraub SE; McNamara D; Graham DMA; Pecora AL; Min J; Wu T; Noh HG; Connors J; Pe Benito R; Choi K; Schultz E; Goldberg SL
    Am J Manag Care; 2017 Dec; 23(12):e416-e420. PubMed ID: 29261249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
    Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
    J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
    Gage MM; Mylander WC; Rosman M; Fujii T; Le Du F; Raghavendra A; Sinha AK; Espinosa Fernandez JR; James A; Ueno NT; Tafra L; Jackson RS
    Ann Oncol; 2018 May; 29(5):1280-1285. PubMed ID: 29788166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer.
    Sail KR; Franzini L; Lairson DR; Du XL
    Value Health; 2012 Jan; 15(1):72-80. PubMed ID: 22264974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011.
    Su KW; Hall J; Soulos PR; Abu-Khalaf MM; Evans SB; Mougalian SS; Rutter CE; Davidoff AJ; Gross CP
    J Geriatr Oncol; 2016 Jan; 7(1):15-23. PubMed ID: 26704661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.
    Enewold L; Geiger AM; Zujewski J; Harlan LC
    Breast Cancer Res Treat; 2015 May; 151(1):149-56. PubMed ID: 25859924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption.
    Dinan MA; Wilson LE; Reed SD; Griggs JJ; Norton EC
    Clin Breast Cancer; 2020 Dec; 20(6):487-494.e1. PubMed ID: 32653473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.
    Oestreicher N; Ramsey SD; McCune JS; Linden HM; Veenstra DL
    Cancer; 2005 Nov; 104(10):2054-62. PubMed ID: 16216002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.